Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

被引：49
|
作者：
Zhu, Andrew X. [1 ]
Finn, Richard S. [2 ]
Galle, Peter R. [3 ]
Llovet, Josep M. [4 ,5 ]
Kudo, Masatoshi [6 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[3] Univ Med Ctr, Mainz, Germany
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[6] Kindai Univ, Osaka, Japan
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(19)30165-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E191 / E191
页数：1
相关论文
共 50 条
  • [21] Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein
    Yen, Chih-Chieh
    Yen, Chia-Jui
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (02) : 157 - 166
  • [22] PATIENT-REPORTED OUTCOMES (PROS) WITH RAMUCIRUMAB VERSUS PLACEBO IN CHINESE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AND ELEVATED ALPHA-FETOPROTEIN FROM THE RANDOMIZED PHASE 3 REACH-2 STUDY
    Chen, X.
    Shao, G.
    Bai, Y.
    Gu, S.
    Gu, K.
    Zhang, Q.
    Zhang, W.
    Liu, J.
    Zhou, L.
    Qin, S.
    VALUE IN HEALTH, 2022, 25 (12) : S19 - S20
  • [23] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)
    Zhu, A. X.
    Finn, R. S.
    Galle, P. R.
    Llovet, J. M.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Cella, D.
    Girvan, A.
    Gable, J.
    Bowman, L.
    Hsu, Y.
    Abada, P. B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 208 - 208
  • [24] REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma
    Chon, Hong Jae
    Kim, Chan
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [25] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
    Zhu, A.
    Finn, R.
    Galle, P.
    Llovet, J.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
    Andrew X. Zhu
    Richard S. Finn
    Yoon-Koo Kang
    Chia-Jui Yen
    Peter R. Galle
    Josep M. Llovet
    Eric Assenat
    Giovanni Brandi
    Kenta Motomura
    Izumi Ohno
    Bruno Daniele
    Arndt Vogel
    Tatsuya Yamashita
    Chih-Hung Hsu
    Guido Gerken
    John Bilbruck
    Yanzhi Hsu
    Kun Liang
    Ryan C. Widau
    Chunxiao Wang
    Paolo Abada
    Masatoshi Kudo
    British Journal of Cancer, 2021, 124 : 1388 - 1397
  • [27] Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
    Zhu, Andrew X.
    Finn, Richard S.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Vogel, Arndt
    Yamashita, Tatsuya
    Hsu, Chih-Hung
    Gerken, Guido
    Bilbruck, John
    Hsu, Yanzhi
    Liang, Kun
    Widau, Ryan C.
    Wang, Chunxiao
    Abada, Paolo
    Kudo, Masatoshi
    BRITISH JOURNAL OF CANCER, 2021, 124 (08) : 1388 - 1397
  • [28] Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites
    Kudo, Masatoshi
    Ikeda, Masafumi
    Galle, Peter R.
    Yamashita, Tatsuya
    Finn, Richard S.
    Liang, Kun
    Wang, Chunxiao
    Sakaguchi, Sachi
    Abada, Paolo
    Widau, Ryan C.
    Zhu, Andrew X.
    HEPATOLOGY RESEARCH, 2021, 51 (06) : 715 - 721
  • [29] Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2)
    Reig, Maria
    Galle, Peter R.
    Kudo, Masatoshi
    Finn, Richard S.
    Llovet, Josep M.
    Schelman, William R.
    Liang, Kun
    Wang, Chunxiao
    Widau, Ryan C.
    Abada, Paolo
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).
    Shao, Guoliang
    Bai, Yuxian
    Chen, Xiaoming
    Gu, Shanzhi
    Gu, Kangsheng
    Yuan, Xianglin
    Widau, Ryan C.
    Zhang, Wanli
    Zhang, Qiang
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16081 - E16081
12345